Adalimumab Autoantibodies in Uveitis Patients: Do We Need Routine Drug Monitoring?
Higher AAA concentrations are associated with lower adalimumab serum levels in uveitis patients. Routine clinical testing is essential for optimal therapeutic drug monitoring to prevent early loss of effectiveness.
Authors
- Vitus A. Knecht (ORCID: https://orcid.org/0000-0002-8843-0181)
- Anne Rübsam (ORCID: https://orcid.org/0000-0001-6202-1710)
- Lynn S. zur Bonsen (ORCID: https://orcid.org/0000-0002-0165-6744)
- Uwe Pleyer (ORCID: https://orcid.org/0000-0002-5569-1473)
- Dominika Pohlmann (ORCID: https://orcid.org/0000-0002-9866-0431)
Institutions
- Humboldt-Universität zu Berlin (DE)
- Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE)
- Freie Universität Berlin (DE)
- Charité - Universitätsmedizin Berlin (DE)
Publication Details
- Journal
- Biomedicines
- Published
- 2024-12-06
- DOI
- https://doi.org/10.3390/biomedicines12122782
- Citations
- 5
- Primary Topic
- Ocular Diseases and Behçet’s Syndrome
- Type
- article
- Field-Weighted Citation Impact
- 2.69
Funders
- Deutsche Forschungsgemeinschaft